Respiratory syncytial virus RSV Vaccines - Biotech, Pharma and Life Science Channel

17:11 EDT 20th October 2014 | BioPortfolio

Respiratory syncytial virus (RSV) infection, which manifests primarily as bronchiolitis and/or viral pneumonia, is the leading cause of lower respiratory tract infection in infants and young children. In the US, RSV LRT infection develops annually in 4-5 million children, and more than 125,000 children are admitted per year for RSV-related illness. RSV disease is the no.1 cause of hospitalization in babies under a year of age in the US. While a monoclonal antibody is commercially available to help prevent RSV disease in infants and children at high risk for severe lung disease from RSV, a RSV vaccine still is not on the market. A number of RSV vaccine candidates have entered clinical development and further are to follow. Also, next generation antibodies against RSV with improved features are in the development pipeline as well as new therapies based on silencing RSV RNA or inhibiting key targets of the virus.

News Articles [993 Associated News Articles listed on BioPortfolio]

OFEV® (nintedanib) Now Available in the United States

RIDGEFIELD, Conn., Oct. 20, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. has announced that OFEV® (nintedanib) capsules are now commercially available in the United S...

News and press releases: Speeding up development of Ebola treatments and vaccines

EMA encourages companies to apply for orphan designation

Address By The Honourable Minister of Health, Professor C.O. Onyebuchi Chukwu

ABUJA, Nigeria, Oct. 20, 2014 /PRNewswire/ -- Nigeria's declaration that it is Ebola-free represents a major milestone of President Jonathan's Administration, according to an official statement from t...

Joint Statement--Ebola: Specialty Nursing and Leadership Organizations Commit to Partnership

ALISO VIEJO, Calif., Oct. 20, 2014 /PRNewswire/ -- The American Association of Critical-Care Nurses, the American Organization of Nurse Executives and the Emergency Nurses Association have issued a jo...

bioCSL Inc. Completes 2014-15 Flu Season Shipment of AFLURIA®

Approximately 16.2 million doses were delivered to providers One of the first U.S. suppliers to complete 2014-2015 seasonal influenza vaccine shipping ...

Cerus Submits Compassionate Use IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent Plasma

The INTERCEPT Pathogen Inactivation Process Offers Potential to Improve Safety of This Emergency Treatment Option for Patients Infected with Ebola Virus Cerus Corporati...

US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine

Phase III clinical study data presented at IDWeek in Philadelphia Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines divisio...

Emergency Physicians Need More Resources to Manage Ebola

WASHINGTON, Oct. 20, 2014 /PRNewswire-USNewswire/ -- The arrival of the Ebola virus in the United States has prompted the nation's emergency physicians to urge policymakers to provide more resources f...

Ocean Bio-Chem, Inc. To Donate Performacide® to Countries Facing Ebola Virus

FORT LAUDERDALE, Fla., Oct. 20, 2014 /PRNewswire/ -- Ocean Bio-Chem, Inc. (NASDAQ:OBCI) announced today that OdorStar Technology, LLC, a wholly-owned subsidiary of Ocean Bio-Chem, Inc., is working wit...

Germicidal Ultraviolet-C Disinfection Poised to Reduce the Rate of Hospital Acquired Infections and Halt the Spread of Ebola Virus

WASHINGTON, Oct. 20, 2014 /PRNewswire/ -- The use of Ultraviolet-C (UV-C) technology is quickly emerging as one of the preeminent means to quickly and effectively disinfect hospital settings, inc...

Events [0 Results]

None

Companies [217 Associated Companies listed on BioPortfolio]

Mucosis B.V.

Mucosis B.V. (Mucosis) is a clinical-stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious disea...

Vaxart, Inc.

Vaxart is a privately owned company developing oral recombinant vaccines based on its proprietary delivery platform. The Vaxart platform is suitable to deliver any protein vaccine...

Global Virus Network (GVN)

The Global Virus Network (GVN) is an independent, not for profit organization, comprised of leading medical virologists from Argentina, Australia, Belgium, Canada, China, France, ...

PharmaJet Inc.

PharmaJet Inc., affiliated with Genesis Medical Technologies, is a needle-free drug delivery technology company. Through the use of its needle-free jet injection technology, the Company’s goal is to...

Mucosis

Mucosis B.V. is a clinical-stage biotechnology company developing novel vaccines on its proprietary Mimopath® platform technology. The Mimopath® platform is being studied fo...

Cell Medica Limited

Cell Medica is a cellular therapeutics company engaged in the development, manufacturing and marketing of T cell immunotherapy approaches for the treatment of infections and cance...

Nanobiotix

NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccine...

Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has ...

Teva Neuroscience Inc.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and...

Meridian Bioscience Inc.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and re...

Clinical Trials [2399 Associated Clinical Trials listed on BioPortfolio]

PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer

Background: - Many cancers produce two proteins, carcinoembryonic antigen (CEA) and mucin-1 (MUC-1). - The PANVAC-V priming vaccine and PANVAC-F boosting vaccine contain human gene...

Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve

Herpes zoster (commonly referred to as "shingles") results from the reactivation of the varicella-zoster virus acquired during a primary infection, usually chickenpox. The virus lays dorm...

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by ...

A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)

A study in two parts (Part A and Part B) to evaluate the responsiveness of various biomarkers of immunity to Varicella-Zoster Virus (VZV) following repeated immunizations with heat treated...

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

The substances BI 201335 and BI 207127 are being developed for the treatment of chronic hepatitis C virus infection. BI 201335 and BI 207127 work by preventing the virus from replicating. ...

Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines

Background: - Seasonal influenza is a major health problem whose impact is typically reduced by vaccination. The H1N1 (swine flu) influenza virus is an emerging pathogen that has the ...

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Subjects With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

This study is to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir fixed-dose combination (LDV/SOF FDC) with or without ribavirin (RBV) in participants with chronic ...

Comparison of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

This study will evaluate the safety, tolerability, and efficacy of treatment with sofosbuvir (SOF)/GS-5816 fixed dose combination (FDC) for 12 weeks compared to treatment with SOF plus rib...

Phase I/II Trial of Early Infusion of Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Allogeneic hematopoetic stem cell transplantation (SCT) is frequently complicated by life threatening viral reactivation. Conventional antiviral therapy is suboptimal for cytomegalovirus ...

The Impact of Arousal Threshold in Obstructive Sleep Apnea

The investigators hypothesis is that obstructive sleep apnea (OSA) patients with a low arousal threshold may wake up too early during a respiratory event, before upper airway muscles can b...

PubMed Articles [7369 Associated PubMed Articles listed on BioPortfolio]

Mouse models of rhinovirus infection and airways disease.

Mouse models are invaluable tools for gaining insight into host immunity during virus infection. Until recently, no practical mouse model for rhinovirus infection was available. Development of infecti...

Reverse genetic engineering of the human rhinovirus serotype 16 genome to introduce an antibody-detectable tag.

The ability to accurately detect viral proteins during infection is essential for virology research, and the lack of specific antibodies can make this detection difficult. Reverse genetic engineering ...

Reverse genetics system for studying human rhinovirus infections.

Human rhinovirus (HRV) contains a 7.2 kb messenger-sense RNA genome which is the template for reproducing progeny viruses after it enters the cytoplasm of a host cell. Reverse genetics refers to the r...

Proteases of human rhinovirus: role in infection.

Human rhinoviruses (HRV) are the major etiological agents of the common cold and asthma exacerbations, with significant worldwide health and economic impact. Although large-scale population vaccinatio...

Capillary electrophoresis, gas-phase electrophoretic mobility molecular analysis, and electron microscopy: effective tools for quality assessment and basic rhinovirus research.

We describe standard methods for propagation, purification, quality control, and physicochemical characterization of human rhinoviruses, using HRV-A2 as an example. Virus is propagated in HeLa-OHIO ce...

Application of FCS in Studies of Rhinovirus Receptor Binding and Uncoating.

Fluorescence correlation spectroscopy (FCS) allows determining diffusion and relaxation properties of fluorescent molecules. It requires only extremely small amounts of sample, down to picomolar conce...

Infectivity assays of human rhinovirus-a and -B serotypes.

Infectivity is a fundamental property of viral pathogens such as human rhinoviruses (HRVs). This chapter describes two methods for measuring the infectivity of HRV-A and -B serotypes: end point diluti...

Growth of Human Rhinovirus in H1-HeLa Cell Suspension Culture and Purification of Virions.

HeLa cell culture is the most widely used system for in vitro studies of the basic biology of human rhinovirus (HRV). It is also useful for making sufficient quantities of virus for experiments that r...

Molecular genotyping of human rhinovirus by using PCR and sanger sequencing.

Human rhinovirus (HRV) is the virus most often associated with acute upper respiratory tract infections. Advances in molecular detection have shown that HRV is also the major viral cause of asthma exa...

Molecular identification and quantification of human rhinoviruses in respiratory samples.

PCR-based molecular assays have become standard diagnostic procedures for the identification and quantification of human rhinoviruses (HRVs) and other respiratory pathogens in most, if not all, clinic...

Medical and Biotech [MESH] Definitions

Vaccines or candidate vaccines used to prevent infection with RESPIRATORY SYNCYTIAL VIRUSES.

Pneumovirus infections caused by the RESPIRATORY SYNCYTIAL VIRUSES. Humans and cattle are most affected but infections in goats and sheep have been reported.

A species of PNEUMOVIRUS causing an important respiratory infection in cattle. Symptoms include fever, conjunctivitis, and respiratory distress.

An acute inflammatory disease of the upper RESPIRATORY TRACT, caused by paramyxoviruses, occurring primarily in infants and young children; the viruses most commonly implicated are PARAINFLUENZA VIRUS TYPE 3; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; and METAPNEUMOVIRUS.

The type species of PNEUMOVIRUS and an important cause of lower respiratory disease in infants and young children. It frequently presents with bronchitis and bronchopneumonia and is further characterized by fever, cough, dyspnea, wheezing, and pallor.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Infectious-diseases
Latest News Clinical Trials Research Drugs Reports Corporate
Infectious diseases are caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi; the diseases can be spread, directly or indirectly, from one person to another. Zoonotic diseases are infectious diseases of animals that can caus...

Advertisement
review and buy Respiratory syncytial virus RSV Vaccines market research data and corporate reports here

Channels Quicklinks